Multidrug therapy (MDT) and leprosy control.
Noordeen
S K
SK
WHO, Geneva.
D002991:Clofazimine / Q000008:administration & dosage / Q000494:pharmacology; D003622:Dapsone / Q000008:administration & dosage; D003906:Developing Countries; D004352:Drug Resistance, Microbial; D004359:Drug Therapy, Combination; D005000:Ethionamide / Q000008:administration & dosage; D006801:Humans; D007194:India / Q000453:epidemiology; D007917:Leprostatic Agents / Q000008:administration & dosage*; D007918:Leprosy / Q000188:drug therapy* / Q000453:epidemiology; D009166:Mycobacterium leprae / Q000187:drug effects; D011515:Prothionamide / Q000008:administration & dosage; D012293:Rifampin / Q000008:administration & dosage / Q000494:pharmacology; D013854:Thioamides / Q000008:administration & dosage / Q000494:pharmacology; D014944:World Health Organization
D007917:Leprostatic Agents; D013854:Thioamides; D011515:Prothionamide; D003622:Dapsone; D002991:Clofazimine; D005000:Ethionamide; D012293:Rifampin